$0.96+0.02 (+2.43%)
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases.
Celularity Inc. in the Healthcare sector is trading at $0.96. The stock is currently near its 52-week low of $0.93, remaining 48.8% below its 200-day moving average. Technical signals show oversold RSI of 20 and bearish MACD signal, explaining why CELU maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent...
Moby summary of NEXGEL, Inc.'s Q4 2025 earnings call
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is...
Celularity ( NASDAQ:CELU ) Second Quarter 2025 Results Key Financial Results Revenue: US$5.74m (down 53% from 2Q 2024...
NasdaqCM:CELU 1 Year Share Price vs Fair Value Explore Celularity's Fair Values from the Community and select yours Key...